GE Healthcare expands cell therapy portfolio with license of STEMCELL Technologies TCell reagents

GE Healthcare today announced an agreement with STEMCELL Technologies Inc. of Vancouver, Canada to provide T-Cell reagents for commercial-scale cell therapy production. Under the agreement, GE Healthcare will commercialize cGMP-grade versions of STEMCELL Technologies’ T-Cell reagents for the isolation, activation, and culture of T-cells in clinical applications. These reagents are critical tools in the development and manufacturing of cell and gene therapies intended for administration to patients. 
Cindy Collins, GM Cell Therapy, GE Healthcare, said: “As cell therapies move to commercialization, the need increases for technologies and industrial capabilities that enable efficient, scalable production of these therapies. The availability of cGMP grade T-Cell reagents significantly expands the complete solution that our customers need to bring cell therapies into widespread clinical practice.”
Allen Eaves, President and CEO of STEMCELL Technologies Inc. said: “This partnership with GE will give our customers the confidence of a path to the clinic with a suite of critical cGMP grade T-cell reagents.  STEMCELL is a recognized leader in cell culture media and cell separation products and GE can leverage our expertise in T-cell isolation, activation and culture to help the industry evolve and make these promising therapies, such as CAR-T cells and TCR-engineered T cells, a clinical reality.”
The exclusive licensing agreement supports GE’s mission to provide an ecosystem of tools and services to the cell therapy industry, and builds on the recent acquisition of Biosafe Group, which added integrated cell bioprocessing systems to GE’s portfolio of manufacturing tools and technologies.
In 2016, GE has made other significant investments in the rapidly growing cell therapy and regenerative medicine industry, including a US $31.5 million co-investment with the Canadian government to create BridGE@CCRM for the acceleration of cellular technologies. In April, GE Ventures and Mayo Clinic announced they would bring capacity and digital infrastructure to the industry with Vitruvian Networks, Inc., an independent platform company accelerating access to cell and gene therapies through advanced, cloud-ready software systems and manufacturing services.
The following proprietary reagents from STEMCELL Technologies will be qualified as cGMP-grade materials and licensed by GE Healthcare:
About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world.  GE (NYSE: GE) works on things that matter – great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at 
About STEMCELL Technologies Inc.
As Scientists Helping Scientists, STEMCELL Technologies Inc. is committed to providing high-quality cell culture media, cell isolation products and accessory reagents for life science research. Driven by science and a passion for quality, STEMCELL Technologies provides over 2000 products to more than 70 countries worldwide. STEMCELL Technologies’ specialty cell culture reagents, instruments and tools are designed to support science along the basic to translational research continuum. To learn more, visit
Media Contacts:
For GE Healthcare:
Erin Bryant
GE Healthcare
+1 203 450 5326
For STEMCELL Technologies Inc.
Andrew Booth
STEMCELL Technologies
+1 604 675 7819